Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jul;68(1):69–73. doi: 10.1038/bjc.1993.288

Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model.

R B Pedley 1, J A Boden 1, R Boden 1, R Dale 1, R H Begent 1
PMCID: PMC1968289  PMID: 8318423

Abstract

The therapeutic efficacy of intact and F(ab')2 fragments of a 131I anti-CEA antibody were compared in an established LS174T colonic xenograft model in nude mice. A single IV dose of either 0.5 mCi (18.5 MBq) intact or 1.0 mCi (37 MBq) F(ab')2 fragments significantly delayed tumour growth, and increased survival time to the same extent. Biodistribution studies showed that the more rapid clearance of the fragments from the circulation improved the tumour: normal tissue ratios found for the intact antibody, but reduced the duration and therefore absolute amount of radioantibody localisation (% injected dose/gram) at the tumour site. The tumours received a similar accumulated beta radiation dose, with 4,065 cGy from 0.5 mCi intact antibody and 4,500 cGy from 1.0 mCi F(ab')2 fragments. The dose rate to the tumour was initially higher for the fragments, but fell off more rapidly as clearance occurred. However, the rapid circulatory clearance resulted in a radiation dose of only 995 cGy to the blood, compared with 2,300 cGy for the intact antibody. This suggests that twice the radiation dose could be delivered to the tumour in the form of fragments for the same blood dose from the intact antibody. Fractionating the 1.0 mCi dose of F(ab')2 into three doses of 0.33 mCi (12.2 MBq), given on days 1, 3 and 5, significantly reduced the therapeutic effect of the treatment. The clinical relevance of these findings is discussed.

Full text

PDF
69

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Begent R. H., Ledermann J. A., Green A. J., Bagshawe K. D., Riggs S. J., Searle F., Keep P. A., Adam T., Dale R. G., Glaser M. G. Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br J Cancer. 1989 Sep;60(3):406–412. doi: 10.1038/bjc.1989.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Begent R. H., Pedley R. B. Antibody targeted therapy in cancer: comparison of murine and clinical studies. Cancer Treat Rev. 1990 Sep;17(2-3):373–378. doi: 10.1016/0305-7372(90)90071-m. [DOI] [PubMed] [Google Scholar]
  3. Buchegger F., Pfister C., Fournier K., Prevel F., Schreyer M., Carrel S., Mach J. P. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments. J Clin Invest. 1989 May;83(5):1449–1456. doi: 10.1172/JCI114037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Buchegger F., Pèlegrin A., Delaloye B., Bischof-Delaloye A., Mach J. P. Iodine-131-labeled MAb F(ab')2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med. 1990 Jun;31(6):1035–1044. [PubMed] [Google Scholar]
  5. Buchegger F., Vacca A., Carrel S., Schreyer M., Mach J. P. Radioimmunotherapy of human colon carcinoma by 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model. Int J Cancer. 1988 Jan 15;41(1):127–134. doi: 10.1002/ijc.2910410123. [DOI] [PubMed] [Google Scholar]
  6. Cheung N. K., Landmeier B., Neely J., Nelson A. D., Abramowsky C., Ellery S., Adams R. B., Miraldi F. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst. 1986 Sep;77(3):739–745. doi: 10.1093/jnci/77.3.739. [DOI] [PubMed] [Google Scholar]
  7. Dale R. G. Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model. Br J Radiol. 1989 Mar;62(735):241–244. doi: 10.1259/0007-1285-62-735-241. [DOI] [PubMed] [Google Scholar]
  8. Fowler J. F. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys. 1990 May;18(5):1261–1269. doi: 10.1016/0360-3016(90)90467-x. [DOI] [PubMed] [Google Scholar]
  9. Harwood P. J., Boden J., Pedley R. B., Rawlins G., Rogers G. T., Bagshawe K. D. Comparative tumour localization of antibody fragments and intact IgG in nude mice bearing a CEA-producing human colon tumour xenograft. Eur J Cancer Clin Oncol. 1985 Dec;21(12):1515–1522. doi: 10.1016/0277-5379(85)90247-0. [DOI] [PubMed] [Google Scholar]
  10. Humm J. L., Cobb L. M. Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med. 1990 Jan;31(1):75–83. [PubMed] [Google Scholar]
  11. Lee E. T., Desu M. M. A computer program for comparing K samples with right-censored data. Comput Programs Biomed. 1972 Nov;2(4):315–321. doi: 10.1016/0010-468x(72)90019-0. [DOI] [PubMed] [Google Scholar]
  12. Looney W. B., Mayo A. A., Allen P. M., Morrow J. Y., Morris H. P. A mathematical evaluation of tumour growth curves in rapid, intermediate and slow growing rat hepatomata. Br J Cancer. 1973 Apr;27(4):341–344. doi: 10.1038/bjc.1973.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pedley R. B., Begent R. H., Boden J. A., Boden R., Adam T., Bagshawe K. D. The effect of radiosensitizers on radio-immunotherapy, using 131I-labelled anti-CEA antibodies in a human colonic xenograft model. Int J Cancer. 1991 Feb 20;47(4):597–602. doi: 10.1002/ijc.2910470420. [DOI] [PubMed] [Google Scholar]
  14. Pedley R. B., Boden J., Keep P. A., Harwood P. J., Green A. J., Rogers G. T. Relationship between tumour size and uptake of radiolabelled anti-CEA in a colon tumour xenograft. Eur J Nucl Med. 1987;13(4):197–202. doi: 10.1007/BF00256491. [DOI] [PubMed] [Google Scholar]
  15. Pedley R. B., Dale R., Boden J. A., Begent R. H., Keep P. A., Green A. J. The effect of second antibody clearance on the distribution and dosimetry of radiolabelled anti-CEA antibody in a human colonic tumor xenograft model. Int J Cancer. 1989 Apr 15;43(4):713–718. doi: 10.1002/ijc.2910430429. [DOI] [PubMed] [Google Scholar]
  16. Schlom J., Molinolo A., Simpson J. F., Siler K., Roselli M., Hinkle G., Houchens D. P., Colcher D. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst. 1990 May 2;82(9):763–771. doi: 10.1093/jnci/82.9.763. [DOI] [PubMed] [Google Scholar]
  17. Sharkey R. M., Pykett M. J., Siegel J. A., Alger E. A., Primus F. J., Goldenberg D. M. Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res. 1987 Nov 1;47(21):5672–5677. [PubMed] [Google Scholar]
  18. Tom B. H., Rutzky L. P., Jakstys M. M., Oyasu R., Kaye C. I., Kahan B. D. Human colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro. 1976 Mar;12(3):180–191. doi: 10.1007/BF02796440. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES